We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

93 hedge funds and large institutions have $276M invested in Dianthus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

0.04% more ownership

Funds ownership: 4% → 4.04% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 97 → 93 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

25% less capital invested

Capital invested by funds: $366M → $276M (-$90.3M)

Holders
93
Holders Change
-4
Holders Change %
-4.12%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
30
Reduced
24
Closed
19
Calls
$86K
Puts
–
Net Calls
+$86K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$4.05M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.99M
3
WP
Woodline Partners
California
+$3.75M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.51M
5
ACM
Aquilo Capital Management
California
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP IV
Massachusetts
-$9.1M
2
EC
EcoR1 Capital
California
-$3.59M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$2.42M
4
O
OrbiMed
New York
-$1.03M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Cerity Partners
51
Cerity Partners
New York
$146K -$43.7K -375 -23%
OC
52
Oppenheimer & Co
New York
$146K – – –
Jacobs Levy Equity Management
53
Jacobs Levy Equity Management
New Jersey
$144K -$967K -8,299 -87%
HF
54
HRT Financial
New York
$142K +$143K +1,224 New
Morgan Stanley
55
Morgan Stanley
New York
$138K -$294K -2,526 -68%
VEA
56
Virtus ETF Advisers
New York
$136K -$7.11K -61 -5%
Deutsche Bank
57
Deutsche Bank
Germany
$133K -$3.96K -34 -3%
AWM
58
Aries Wealth Management
Maine
$131K – – –
EW
59
Evoke Wealth
California
$131K – – –
ProShare Advisors
60
ProShare Advisors
Maryland
$119K -$13.6K -117 -10%
AIG
61
American International Group
New York
$119K -$2.91K -25 -2%
California State Teachers Retirement System (CalSTRS)
62
California State Teachers Retirement System (CalSTRS)
California
$117K -$184K -1,577 -61%
PPA
63
Parametric Portfolio Associates
Washington
$111K +$111K +950 New
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$109K -$78.4K -673 -42%
AG
65
Algert Global
California
$109K -$65K -558 -37%
Vontobel Holding
66
Vontobel Holding
Switzerland
$108K +$108K +924 New
SG Americas Securities
67
SG Americas Securities
New York
$107K +$107K +915 New
Invesco
68
Invesco
Georgia
$95K +$14.6K +125 +18%
VOYA Investment Management
69
VOYA Investment Management
Georgia
$90K – – –
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$80K – – –
EGM
71
Engineers Gate Manager
New York
$74K +$73.5K +631 New
Royal Bank of Canada
72
Royal Bank of Canada
Ontario, Canada
$49K +$3.26K +28 +7%
Citigroup
73
Citigroup
New York
$47K +$10.6K +91 +29%
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$39.8K +$32.4K +278 +434%
CAPTRUST Financial Advisors
75
CAPTRUST Financial Advisors
North Carolina
$31K – – –
1 2
3
4 5

DNTH Hedge Fund Activity: Q3 2021 in Review

93 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2021, worth a combined $276M — down 25% from $366M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of DNTH and 15 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 30 added.

The largest buyer was Casdin Capital, adding an estimated $4.05M. The largest seller was TRV GP IV, cutting an estimated $9.1M.

  • 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2021, down from 97 in Q2 2021.
  • Funds reported $276M of Dianthus Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
  • 15 funds opened new Dianthus Therapeutics positions in Q3 2021 and 19 closed out, a net change of -4 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2021 was Casdin Capital, an estimated $4.05M added.
  • The largest Dianthus Therapeutics seller in Q3 2021 was TRV GP IV, an estimated $9.1M sold.

Based on aggregated 13F filings for Q3 2021.